Fobi Signs Marketing Deal with Abbot’s Butcher, A Premium US Plant-Based Protein Company

Fobi AI Inc. (FOBI: TSXV; FOBIF: OTCQB) (the “Company” or “FOBI”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce the signing of a deal on January 17th to provide Abbot’s Butcher, a premium plant-based protein brand, with Fobi’s Qples coupon platform.     Deal with Abbot’s Butcher […]

Continue Reading
Neurologist engineer doctor monitoring brain activity evolution during neuroscience experiment

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Dr. Cheryl Wellington to its scientific advisory board (SAB).   Dr. Cheryl Wellington, Professor of Pathology and Laboratory […]

Continue Reading

Fobi Integrates With Square, Offering Real-Time Data Analytics to Retailers Around the Globe

Fobi AI Inc. (FOBI: TSXV; FOBIF: OTCQB) (the “Company” or “FOBI”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce the partnership and integration of its Fobi platform with Square, owned by global technology company, Block, Inc. — formerly Square, Inc. The partnership includes the availability of the […]

Continue Reading

Rockridge Resources Reports 4.06% and 1.60% Copper in Grab Samples and Identifies New Target West of Gilbert Lake at its Knife Lake Project

Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) is pleased to announce further sampling and prospecting results from the 2021 exploration program at the  Knife Lake Copper VMS Project located in Saskatchewan, Canada (the “Knife Lake Project” or “Property”). The Knife Lake Project, consisting of 82 claims totaling 56,865 hectares (140,516 acres), is an advanced-stage […]

Continue Reading

ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses. Schizophrenia is a clinical […]

Continue Reading

Skyharbour’s Partner Company Azincourt Energy Provides Update on Camp Construction and Drill Mobilization at East Preston Uranium Project, Saskatchewan

Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt”) is pleased to announce that construction of the exploration camp for the winter 2022 exploration program is underway at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, Canada.   Project Location – Western Athabasca Basin, Saskatchewan, Canada: https://www.skyharbourltd.com/_resources/maps/Sky_EastPreston_20211209.jpg   Discovery Mining Services is […]

Continue Reading

FOBI Announces Definitive Agreement To Acquire Passworks S.A. for €400,000 To Further Expand FOBI’s Global Digital Wallet Pass Portfolio

FOBI AI Inc. (TSXV: FOBI, OTCQB: FOBIF) (the “Company” or “FOBI”), a global leader in providing real-time data analytics through artificial intelligence to drive operational efficiencies and profitability, is pleased to announce that it has entered into a share purchase agreement (the “SPA”) with Passworks to acquire all of the issued and outstanding shares (the “Target […]

Continue Reading

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 […]

Continue Reading